冠状动脉疾病
医学
药品
心脏病学
疾病
内科学
药理学
作者
Antonio Greco,Giovanni Di Leo,Marco Spagnolo,Daniele Giacoppo,Davide Capodanno
标识
DOI:10.1080/17434440.2025.2474179
摘要
Trials of DCB are heterogeneous with respect to population, sample size, follow-up, anatomical pattern, and device used. Furthermore, they usually have limited statistical power for clinical endpoints. Based on current knowledge, DES may be preferrable for DES-ISR, de novo lesions in large vessels and for the treatment of the main branch in true bifurcations, with DCB approved for small-vessel disease and selected ISR lesions. Ongoing trials are expected to provide definitive insights into the efficacy and safety of DCB in different scenarios.
科研通智能强力驱动
Strongly Powered by AbleSci AI